Paul Klauser
paulklauser.bsky.social
Paul Klauser
@paulklauser.bsky.social
Research Fellow at MSKCC | Developing radiopharmaceuticals to diagnose and treat cancer ☢️
Reposted by Paul Klauser
Had a blast this weekend at the Badger Trail Races— super ULTRA mega congrats to @colehoneycutt.bsky.social and @paulklauser.bsky.social on their first 100M finishes!!!!

Together, we ran 303.3 miles in under 75 hours, burning 50,000+ calories along the way!
August 5, 2025 at 11:50 AM
Reposted by Paul Klauser
🎉 Congratulations to #MSKPostdoc Paul Klauser (@paulklauser.bsky.social), mentored by @lewislabmskcc.bsky.social & @caleblareau.bsky.social, on being awarded the prestigious Damon Runyon Quantitative Biology Fellowship! 👏
Congratulations to the newest Damon Runyon Quantitative Biology Fellows, five exceptional early-career scientists who are using state-of-the-art computational tools to bring cancer biology into high resolution!
June 5, 2025 at 3:50 PM
Reposted by Paul Klauser
Congratulations to the newest Damon Runyon Quantitative Biology Fellows, five exceptional early-career scientists who are using state-of-the-art computational tools to bring cancer biology into high resolution!
June 4, 2025 at 7:57 PM
Reposted by Paul Klauser
The Lewis Lab aka the “Cycletrons” turning out for Stand up to Cancer raising money for treating rare cancers. I was asked to say a few words at the beginning of the ride…. Every penny really does make a difference. @cycleforsurvival.bsky.social @mskcancercenter.bsky.social
March 8, 2025 at 11:42 AM
Reposted by Paul Klauser
Out now at Clin Cancer Research we characterized a new Trop-2 antibody for rapid tumor detection in pancreatic, ovarian, and prostate cancers. We also leveraged pretargeting for rapid, high-capacity imaging. Huge thanks to our collaborators for the amazing work!

aacrjournals.org/clincancerre...
Pretargeted Trop-2 immunoPET for rapid, selective detection of pancreatic tumors
Abstract. Purpose: Recent clinical advances with the approval of antibody-drug conjugates targeting Trop-2 such as sacituzumab-govitecan and datopotomab-deruxtecan have garnered tremendous interest fo...
aacrjournals.org
January 23, 2025 at 10:30 PM
Amazing Day! Couldn't have done it without this stellar group 🤩
First annual Manhattan perimeter run with this crew! HBD @paulklauser.bsky.social and thanks to @isabelfulcher.bsky.social for planning a perfect route!
December 16, 2024 at 6:39 PM